Gå ubegrenset med Magzter GOLD

Gå ubegrenset med Magzter GOLD

Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare

$149.99
 
$74.99/År

Prøve GULL - Gratis

Enterprise Risk Management (ERM): A critical imperative for India's pharma sector

Express Pharma

|

May 2025

Gurmeet Singh, Procurement Director at Alfa Pharma, highlights how risk-resilient practices can strengthen the Indian pharma sector's global standing

Enterprise Risk Management (ERM): A critical imperative for India's pharma sector

The Indian pharmaceutical industry is one of the largest globally, known for its significant role in the production of generic drugs, contributing around 20 per cent of the global supply by volume. The industry is crucial in meeting global healthcare needs, especially in producing affordable medicines. However, the sector faces several supply chain challenges, affecting both domestic and international operations. However, the sector faces numerous risks and disruptions, including geopolitical tensions, pandemics, supply chain failures, and regulatory challenges. To address these challenges, there is an emergent need for the sector to develop and embrace a comprehensive Enterprise Risk Management (ERM) framework tailored to the unique needs of Indian pharma companies. Some of the key challenges faced by Indian Pharma are the following:

1. Dependence on China for imports of basic chemicals and input raw materials.

2. Regulatory hurdles and need to comply with USFDA and European Medicine Agency regulations.

3. Logistical bottlenecks, the complex transport network, port congestion, road conditions and inadequate cold chain infrastructure.

4. Quality control issues arising from deviation from the Standard Operating Procedures resulting in product failures and product recalls impacting the company’s reputation and revenues.

5. Supply chain disruptions arising out of unforeseen pandemics, further getting compounded by sudden price increase, contract cancellations and non-availability of critical raw materials.

6. Inadequate technology integration, lower focus on innovation and minimal R&D spend. Indian companies lag in adoption of advanced technologies like block chain, AI in drug discovery and use of robotics.

7. Environmental impact due to pollution from pharmaceutical waste. Many units face a sudden stoppage due to non-compliance and risks thereof.

FLERE HISTORIER FRA Express Pharma

Express Pharma

Express Pharma

Flexotherm Heating Tapes & Cords

Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling

time to read

1 mins

October 2025

Express Pharma

Express Pharma

DRIVING INDIA'S INNOVATION EDGE

Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership

time to read

16 mins

October 2025

Express Pharma

Express Pharma

Al compass: Transforming pharma commercialisation

As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations

time to read

7 mins

October 2025

Express Pharma

Express Pharma

PRIME NEO: New age doors from Gandhi Automation

Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.

time to read

1 mins

October 2025

Express Pharma

Express Pharma

Unani Medicine: At crossroads of tradition and modernity

Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana

time to read

7 mins

October 2025

Express Pharma

Express Pharma

Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand

The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.

time to read

1 min

October 2025

Express Pharma

Express Pharma

Sustainable packaging with Romaco and Liveo Research

Recycable blister packs

time to read

3 mins

October 2025

Express Pharma

Express Pharma

With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here

As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.

time to read

3 mins

October 2025

Express Pharma

Express Pharma

Cell therapy's next chapter: Industry embraces in-vivo innovation

Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases

time to read

4 mins

October 2025

Express Pharma

Express Pharma

Research misconduct ...can delay meaningful and reliable discoveries

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

time to read

6 mins

October 2025

Listen

Translate

Share

-
+

Change font size